Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Susan Bare"'
Publikováno v:
The FASEB Journal. 36
Autor:
Utsav Sharma, Jun Sun, Kelsie Medina-Saenz, Susan Bare, Philip Miller, Manuel Picon-Ruiz, Joyce Slingerland, Dorraya El-Ashry, Marc Lippman
Publikováno v:
Cancer Research. 82:P5-06
Background: Metastatic disease is the foremost cause of breast cancer (BC) related mortality in women. One of the crucial challenges in reducing metastasis-related mortality is in identifying and understanding why certain BCs metastasize and recur. A
Publikováno v:
Alternativecomplementary therapies : a new bimonthly publication for health care practitioners. 22(5)
Background: Complementary and alternative medicine (CAM) could be one option to address perceived insufficient milk (PIM), but there are few data comparing the effectiveness, acceptability, and safety of various CAM therapies. The purpose of this stu
Autor:
Susan Barendrecht, An Schreurs, Stefanie Geissler, Victor Sabanov, Victoria Ilse, Vera Rieckmann, Rico Eichentopf, Anja Künemund, Benjamin Hietel, Sebastian Wussow, Katrin Hoffmann, Kerstin Körber-Ferl, Ravi Pandey, Gregory W. Carter, Hans-Ulrich Demuth, Max Holzer, Steffen Roßner, Stephan Schilling, Christoph Preuss, Detlef Balschun, Holger Cynis
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-23 (2023)
Abstract Background Hyperphosphorylation and intraneuronal aggregation of the microtubule-associated protein tau is a major pathological hallmark of Alzheimer’s disease (AD) brain. Of special interest is the effect of cerebral amyloid beta depositi
Externí odkaz:
https://doaj.org/article/a9c1be2cbfd647cb8dd039ae107ce4ee
Autor:
Kathrin Gnoth, Anke Piechotta, Martin Kleinschmidt, Sandra Konrath, Mathias Schenk, Nadine Taudte, Daniel Ramsbeck, Vera Rieckmann, Stefanie Geissler, Rico Eichentopf, Susan Barendrecht, Maike Hartlage-Rübsamen, Hans-Ulrich Demuth, Steffen Roßner, Holger Cynis, Jens-Ulrich Rahfeld, Stephan Schilling
Publikováno v:
Alzheimer’s Research & Therapy, Vol 12, Iss 1, Pp 1-20 (2020)
Abstract Background Amyloid β (Aβ)-directed immunotherapy has shown promising results in preclinical and early clinical Alzheimer’s disease (AD) trials, but successful translation to late clinics has failed so far. Compelling evidence suggests th
Externí odkaz:
https://doaj.org/article/2c961e761ce84b74a60f7925a3750699